Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis

scientific article published on 30 May 2019

Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41391-019-0156-Z
P698PubMed publication ID31147628

P50authorShahrokh ShariatQ7462263
M Kardoust PariziQ85887779
Markus HartenbachQ88687449
Shoji KimuraQ89482497
Florian JanischQ89499908
Takehiro IwataQ91806148
Shin EgawaQ92694544
Beat FoersterQ39051546
Mohammad AbufarajQ39051577
Nicola FossatiQ41202163
P2093author name stringAlberto Briganti
P2860cites workInitial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.Q48370281
Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.Q52984262
68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.Q52985406
Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.Q52991043
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial prQ88565499
Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomesQ89222149
Ga-labeled Prostate-specific Membrane Antigen Ligand-positron-emission Tomography: Still Just the Tip of the IcebergQ89379875
Accuracy of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography for the Detection of Lymph Node Metastases Before Salvage LymphadenectomyQ90517559
Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node PathologyQ91177742
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review andQ91655726
Quantifying heterogeneity in a meta-analysisQ27860672
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studiesQ27861031
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviewsQ29619492
Predicting 15-year prostate cancer specific mortality after radical prostatectomyQ33759725
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerQ35043569
Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysisQ36065223
Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literatureQ37978983
Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage LymphadenectomyQ38853977
Radiolabeled choline PET/CT before salvage lymphadenectomy dissection: a systematic review and meta-analysis.Q38934646
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentQ38939206
Role of salvage lymph node dissection in prostate cancerQ38943636
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerQ38945683
Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancerQ39009150
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomyQ39724803
Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinomaQ40327142
Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.Q40468376
Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term SurvivalQ40955829
Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate CancerQ42257970
Bivariate random effects meta-analysis of ROC curves.Q45923370
Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patientsQ47115390
P433issue1
P304page(s)1-10
P577publication date2019-05-30
P1433published inProstate Cancer and Prostatic DiseasesQ2108326
P1476titlePerformance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis
P478volume23

Reverse relations

Q99583250The role of salvage lymph node dissection and PSMA-PET in recurrent prostate cancercites workP2860

Search more.